Responses
Correspondence response
Response to: ‘Comment on ‘Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab’’ by Pethoe-Schramm et al
Compose a Response to This Article
Other responses
No responses have been published for this article.